News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
397,713 Results
Type
Article (23657)
Company Profile (157)
Press Release (373899)
Section
Business (115296)
Career Advice (665)
Deals (19030)
Drug Delivery (65)
Drug Development (47655)
Employer Resources (81)
FDA (11238)
Job Trends (9961)
News (195829)
Policy (17705)
Tag
Academia (2090)
Africa (378)
Alliances (33873)
Alzheimer's disease (771)
Approvals (11200)
Arizona (78)
Artificial intelligence (65)
Asia (31542)
Australia (3136)
Bankruptcy (110)
Best Places to Work (8341)
Biotechnology (106)
Breast cancer (60)
C2C Services and Suppliers (46680)
California (1313)
Canada (614)
Cancer (500)
Career advice (550)
Cell therapy (113)
China (176)
Clinical research (38308)
Collaboration (169)
Colorado (62)
Connecticut (65)
COVID-19 (1809)
Cystic fibrosis (52)
Data (358)
Diabetes (62)
Diagnostics (4096)
Drug pricing (54)
Earnings (36589)
Employer resources (71)
Europe (55110)
Events (58264)
Executive appointments (144)
FDA (11483)
Florida (212)
Funding (151)
Gene therapy (69)
Georgia (59)
GLP-1 (327)
Government (2700)
Healthcare (13565)
Hotbed/Location (261892)
Illinois (211)
Indiana (126)
Infectious disease (1838)
Inflammatory bowel disease (61)
Interviews (94)
IPO (7938)
Job creations (1808)
Job search strategy (510)
Kansas (52)
Layoffs (182)
Legal (3202)
Lung cancer (111)
Manufacturing (92)
Maryland (327)
Massachusetts (1053)
Medical device (10263)
Medtech (10266)
Mergers & acquisitions (11143)
Metabolic disorders (155)
Michigan (80)
Minnesota (170)
Neuroscience (874)
New Jersey (476)
New York (489)
NextGen Class of 2024 (4491)
Non-profit (3501)
North Carolina (445)
Northern California (570)
Obesity (87)
Ohio (90)
Opinion (112)
Patents (53)
Pennsylvania (388)
People (34407)
Phase I (11483)
Phase II (16604)
Phase III (13358)
Pipeline (99)
Policy (57)
Postmarket research (1466)
Preclinical (3805)
Press Release (67)
Radiopharmaceuticals (190)
Rare diseases (102)
Real estate (4405)
Regulatory (12524)
Research institute (1913)
Resumes & cover letters (93)
South America (566)
Southern California (535)
Startups (2314)
Texas (189)
United States (6253)
Vaccines (361)
Washington State (104)
Weight loss (72)
Date
Today (138)
Last 7 days (442)
Last 30 days (1914)
Last 365 days (24840)
2024 (18739)
2023 (26230)
2022 (34782)
2021 (36470)
2020 (35318)
2019 (32542)
2018 (24693)
2017 (21001)
2016 (20282)
2015 (22973)
2014 (16505)
2013 (13552)
2012 (14569)
2011 (14720)
2010 (12419)
397,713 Results for "astrazeneca innovation center china".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Diabetes
Innovent’s Lilly-Partnered Type 2 Diabetes Drug Aces Phase III in China, Inches Closer to Approval
Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.
July 22, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug
For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.
October 7, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus in Chengdu, China.
February 5, 2024
·
4 min read
Policy
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FibroGen, Inc. announced that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc.
February 26, 2024
·
4 min read
News
Moffitt Cancer Center Announces Strategic Collaboration with AstraZeneca to Accelerate Oncology Cell Therapies
September 13, 2024
·
2 min read
Policy
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
China Medical System Holdings Limited is pleased to announce that on 11 June 2024, the New Drug Application of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets has been approved by the National Medical Products Administration of China.
June 18, 2024
·
7 min read
Biotech Bay
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
Innovent Biologics, Inc. announced that the New Drug Application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody, has been accepted and granted priority review designation by the Center for Drug Evaluation of the China National Drug Administration for the treatment of Thyroid Eye Disease.
May 20, 2024
·
10 min read
Approvals
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer
The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.
August 14, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval
AstraZeneca is seeking a fixed-duration approval for Calquence, which will allow patients with chronic lymphocytic leukemia to take breaks from the therapy and prevent excessive toxicities and drug resistance.
July 30, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
AnHeart Therapeutics and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor.
March 4, 2024
·
7 min read
1 of 39,772
Next
